Protherics PLC
Notification of Major Interest in Shares
London, UK; Brentwood, TN, US; 20 November 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, announces that, on 19
November 2008, the following notification of interest in the ordinary
share capital of the Company was received from Aviva plc.
1. Reason for the notification (please tick the appropriate
box or boxes)
A disposal voting rights X
An acquisition or disposal of financial instruments which may
result in the acquisition of shares already issued to which
voting rights are attached
An event changing the breakdown of voting rights
Other (please specify):
2. Full name of person(s) subject to the Aviva plc & its
notification obligation: subsidiaries
3. Full name of shareholder(s) (if different from Registered
Holder: 2.):
BNY Norwich Union
Nominees Limited
5,959,368*
Chase GA Group
Nominees Limited
19,321,240*
Chase Nominees
Limited
879,543*
CUIM Nominee Limited
4,366,418*
Vidacos Nominees
Limited
65,125*
*denotes direct
interest
BNP Paribas - London
636,429
Chase Nominees
Limited
3,065,451
State Street
Nominees Limited
9,428,137
Vidacos Nominees
Limited
1,603,080
4. Date of the transaction (and date on which the 18 November 2008threshold is crossed or reached if different):
5. Date on which issuer notified: 19 November 2008
6. Threshold(s) that is/are crossed or reached: 13% to 12% Change
at Combined Interest
level
7. Notified details:
A: Voting rights attached to shares
Class/type Situation previous
of shares to the Triggering
if possible transaction
using the
ISIN CODE
Number of Number of voting
Shares Rights
Ordinary
Shares 45,971,166 45,971,166
GB0007029209
Resulting situation after the trigger transaction
Number of Number of voting & of voting rights
Shares rights
Direct Direct Indirect Direct Indirect
30,591,694 30,591,694 14,733,097 8.73% 4.20%
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting rights that % of
financial date Conversion may be acquired if the voting
instrument Period/ instrument is exercised/ rights
Date converted.
N/A
Total (A+B)
Number of voting rights % of voting rights
45,324,791 12.93%
8. Chain of controlled undertakings through which the voting rights and
/or the financial instruments are effectively held, if applicable :
The voting rights are managed and controlled by Aviva Investors Global
Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited:
- Aviva plc (Parent Company)
- Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)
- Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva
Group Holdings Limited)
- Aviva Investors Global Services Limited (wholly owned subsidiary of
Aviva Investors Holdings Limited)
Proxy Voting:
9. Name of the proxy holder:
See Section 3
10. Number of voting rights proxy holder will cease to
hold:
11. Date on which proxy holder will cease to hold voting
rights:
12. Additional Figures are based on a revised total number of
information: voting rights of 350,427,481
/ Ends /
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com